ACRV
Acrivon Therapeutics, Inc.
Price Chart
Latest Quote
$1.81
Current Price| Previous Close | $1.79 |
| Open | $1.76 |
| Day High | $1.87 |
| Day Low | $1.73 |
| Volume | 630,601 |
Stock Information
| Shares Outstanding | 31.56M |
| Total Debt | $2.99M |
| Cash Equivalents | $129.25M |
| Net Income | $-81.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $57.11M |
| EPS (TTM) | $-2.12 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.02 |
| Debt to Earnings | -0.05 |
| Current Ratio | 10.55 |
| Quick Ratio | 10.43 |
| Return on Equity | -45.57% |
| Avg FCF Growth | 95.32% |
| FCF Yield | -119.82% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.81 | 634,476 |
| 2026-01-30 | $1.79 | 624,800 |
| 2026-01-29 | $1.88 | 563,600 |
| 2026-01-28 | $1.89 | 1,031,000 |
| 2026-01-27 | $1.98 | 572,100 |
| 2026-01-26 | $1.94 | 1,361,800 |
| 2026-01-23 | $2.05 | 857,000 |
| 2026-01-22 | $2.03 | 1,171,700 |
| 2026-01-21 | $2.09 | 957,800 |
| 2026-01-20 | $1.96 | 2,153,500 |
| 2026-01-16 | $1.98 | 2,022,600 |
| 2026-01-15 | $1.87 | 1,258,700 |
| 2026-01-14 | $1.83 | 2,119,500 |
| 2026-01-13 | $1.70 | 1,530,900 |
| 2026-01-12 | $1.63 | 2,883,500 |
| 2026-01-09 | $1.75 | 4,666,500 |
| 2026-01-08 | $1.93 | 42,742,000 |
| 2026-01-07 | $2.95 | 3,058,200 |
| 2026-01-06 | $3.01 | 3,287,900 |
| 2026-01-05 | $2.29 | 547,500 |
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
📰 Latest News
Penny Stocks To Watch In January 2026
Simply Wall St. • 2026-01-19T12:05:09Z
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares
Simply Wall St. • 2026-01-18T13:18:09Z
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Zacks • 2026-01-07T14:40:03Z
3 Promising Penny Stocks With Market Caps Over $70M
Simply Wall St. • 2025-12-11T12:05:08Z
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT
Insider Monkey • 2025-11-29T06:26:00Z
3 Promising Penny Stocks With Market Caps Over $20M
Simply Wall St. • 2025-11-04T18:05:11Z
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
TipRanks • 2025-11-02T10:05:00Z
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap
Simply Wall St. • 2025-10-02T18:05:10Z
Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Simply Wall St. • 2025-07-22T14:12:50Z
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
TipRanks • 2025-05-17T16:30:10Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $89,199,000 | $67,103,000 | $32,657,000 | $16,184,000 |
| Other Income Expense | $-558,000 | $-322,000 | $1,490,000 | $-59,000 |
| Other Non Operating Income Expenses | $-558,000 | $-322,000 | $1,490,000 | $-59,000 |
| Net Non Operating Interest Income Expense | $9,201,000 | $7,037,000 | - | - |
| Operating Expense | $89,199,000 | $67,103,000 | $32,657,000 | $16,184,000 |
| General And Administrative Expense | $25,207,000 | $21,079,000 | $8,708,000 | $2,466,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Net Interest Income | $9,201,000 | $7,037,000 | - | - |
| Interest Income | $9,201,000 | $7,037,000 | - | - |
| Normalized Income | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Net Income From Continuing And Discontinued Operation | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Total Operating Income As Reported | $-89,199,000 | $-67,103,000 | $-32,657,000 | $-16,184,000 |
| Net Income Common Stockholders | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Net Income | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Net Income Including Noncontrolling Interests | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Net Income Continuous Operations | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Pretax Income | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Interest Income Non Operating | $9,201,000 | $7,037,000 | - | - |
| Operating Income | $-89,199,000 | $-67,103,000 | $-32,657,000 | $-16,184,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.38 | $-2.74 | $-7.56 | $-1.26 |
| Basic EPS | $-2.38 | $-2.74 | $-7.56 | $-1.26 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-88,193,000 | $-66,567,000 | $-32,293,000 | $-16,147,000 |
| Reconciled Depreciation | $1,006,000 | $536,000 | $364,000 | $37,000 |
| EBITDA (Bullshit earnings) | $-88,193,000 | $-66,567,000 | $-32,293,000 | $-16,147,000 |
| EBIT | $-89,199,000 | $-67,103,000 | $-32,657,000 | $-16,184,000 |
| Diluted Average Shares | $33,791,817 | $22,078,190 | $4,121,912 | $12,909,823 |
| Basic Average Shares | $33,791,817 | $22,078,190 | $4,121,912 | $12,909,823 |
| Diluted NI Availto Com Stockholders | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Research And Development | $63,992,000 | $46,024,000 | $23,949,000 | $13,718,000 |
| Selling General And Administration | $25,207,000 | $21,079,000 | $8,708,000 | $2,466,000 |
| Other Gand A | $7,105,000 | $6,460,000 | $3,640,000 | $1,100,000 |
| Salaries And Wages | $18,102,000 | $14,619,000 | $5,068,000 | $1,366,000 |
| Total Unusual Items | - | - | - | $-80,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $-80,000 |
| Gain On Sale Of Security | - | - | - | $-80,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Total Assets | $196,588,000 | $138,265,000 | $181,226,000 | $106,587,000 |
| Total Non Current Assets | $14,959,000 | $8,573,000 | $49,131,000 | $6,179,000 |
| Other Non Current Assets | $198,000 | $414,000 | $388,000 | $388,000 |
| Non Current Deferred Assets | $1,647,000 | $251,000 | $0 | - |
| Investmentin Financial Assets | $5,089,000 | $0 | - | - |
| Current Assets | $181,629,000 | $129,692,000 | $132,095,000 | $100,408,000 |
| Other Current Assets | $2,149,000 | $2,234,000 | $4,344,000 | $805,000 |
| Cash Cash Equivalents And Short Term Investments | $179,480,000 | $127,458,000 | $127,751,000 | $99,603,000 |
| Cash And Cash Equivalents | $39,818,000 | $36,015,000 | $29,519,000 | $99,603,000 |
| Prepaid Assets | - | - | - | $805,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $3,645,000 | $4,644,000 | $4,961,000 | $5,628,000 |
| Long Term Debt And Capital Lease Obligation | $2,588,000 | $3,767,000 | $4,235,000 | $4,964,000 |
| Current Debt And Capital Lease Obligation | $1,057,000 | $877,000 | $726,000 | $664,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $19,802,000 | $17,070,000 | $10,751,000 | $130,396,000 |
| Total Non Current Liabilities Net Minority Interest | $2,588,000 | $3,767,000 | $4,235,000 | $127,482,000 |
| Current Liabilities | $17,214,000 | $13,303,000 | $6,516,000 | $2,914,000 |
| Payables And Accrued Expenses | $10,701,000 | $8,566,000 | $3,059,000 | $1,517,000 |
| Payables | $758,000 | $5,048,000 | $904,000 | $964,000 |
| Accounts Payable | $758,000 | $5,048,000 | $904,000 | $964,000 |
| Current Deferred Liabilities | - | $0 | $69,000 | $66,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Current Notes Payable | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Total Equity Gross Minority Interest | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Stockholders Equity | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Gains Losses Not Affecting Retained Earnings | $447,000 | $-83,000 | $-95,000 | $0 |
| Other Equity Adjustments | $447,000 | $-83,000 | $-95,000 | - |
| Retained Earnings | $-196,976,000 | $-116,420,000 | $-56,032,000 | $-24,865,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $122,518,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $31,231,264 | $22,522,644 | $21,920,402 | $18,809,823 |
| Share Issued | $31,231,264 | $22,522,644 | $21,920,402 | $18,809,823 |
| Tangible Book Value | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Invested Capital | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Working Capital | $164,415,000 | $116,389,000 | $125,579,000 | $97,494,000 |
| Capital Lease Obligations | $3,645,000 | $4,644,000 | $4,961,000 | $5,628,000 |
| Total Capitalization | $176,786,000 | $121,195,000 | $170,475,000 | $-23,809,000 |
| Additional Paid In Capital | $373,284,000 | $237,675,000 | $226,580,000 | $1,054,000 |
| Capital Stock | $31,000 | $23,000 | $22,000 | $2,000 |
| Common Stock | $31,000 | $23,000 | $22,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,588,000 | $3,767,000 | $4,235,000 | $4,964,000 |
| Current Capital Lease Obligation | $1,057,000 | $877,000 | $726,000 | $664,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,456,000 | $3,860,000 | $2,662,000 | $667,000 |
| Current Accrued Expenses | $9,943,000 | $3,518,000 | $2,155,000 | $553,000 |
| Investments And Advances | $5,089,000 | $0 | $41,881,000 | $0 |
| Available For Sale Securities | $5,089,000 | - | - | - |
| Net PPE | $8,025,000 | $7,908,000 | $6,862,000 | $5,791,000 |
| Accumulated Depreciation | $-1,962,000 | $-956,000 | $-420,000 | $-56,000 |
| Gross PPE | $9,987,000 | $8,864,000 | $7,282,000 | $5,847,000 |
| Construction In Progress | $58,000 | $1,308,000 | $0 | - |
| Other Properties | $3,554,000 | $4,429,000 | $4,770,000 | $5,501,000 |
| Machinery Furniture Equipment | $6,375,000 | $3,127,000 | $2,512,000 | $346,000 |
| Other Short Term Investments | $139,662,000 | $91,443,000 | $98,232,000 | $0 |
| Current Deferred Revenue | - | $0 | $69,000 | $66,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-68,437,000 | $-43,929,000 | $-32,283,000 | $-14,220,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-65,669,000 | $-42,641,000 | $-30,117,000 | $-13,982,000 |
| Cash Flow From Continuing Operating Activities | $-65,669,000 | $-42,641,000 | $-30,117,000 | $-13,982,000 |
| Operating Gains Losses | - | - | - | $255,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-2,768,000 | $-1,288,000 | $-2,166,000 | $-238,000 |
| Investing Cash Flow | $-51,771,000 | $50,717,000 | $-141,676,000 | $-238,000 |
| Cash Flow From Continuing Investing Activities | $-51,771,000 | $50,717,000 | $-141,676,000 | $-238,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $69,997,000 | $0 | $104,458,000 | $112,220,000 |
| Financing Cash Flow | $121,027,000 | $-1,554,000 | $101,709,000 | $112,221,000 |
| Cash Flow From Continuing Financing Activities | $121,027,000 | $-1,554,000 | $101,709,000 | $112,221,000 |
| Net Other Financing Charges | $-9,063,000 | $-2,329,000 | $-2,773,000 | - |
| Net Common Stock Issuance | $69,997,000 | $0 | $104,458,000 | $0 |
| Common Stock Issuance | $69,997,000 | $0 | $104,458,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $112,220,000 |
| Preferred Stock Issuance | - | - | $0 | $112,220,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $40,016,000 | $36,429,000 | $29,907,000 | $99,991,000 |
| Beginning Cash Position | $36,429,000 | $29,907,000 | $99,991,000 | $1,990,000 |
| Changes In Cash | $3,587,000 | $6,522,000 | $-70,084,000 | $98,001,000 |
| Proceeds From Stock Option Exercised | $60,093,000 | $775,000 | $24,000 | $1,000 |
| Net Investment Purchase And Sale | $-49,003,000 | $52,005,000 | $-139,510,000 | $0 |
| Sale Of Investment | $153,923,000 | $108,533,000 | $10,668,000 | $0 |
| Purchase Of Investment | $-202,926,000 | $-56,528,000 | $-150,178,000 | $0 |
| Net PPE Purchase And Sale | $-2,768,000 | $-1,288,000 | $-2,166,000 | $-238,000 |
| Purchase Of PPE | $-2,768,000 | $-1,288,000 | $-2,166,000 | $-238,000 |
| Change In Working Capital | $2,438,000 | $8,138,000 | $-1,532,000 | $328,000 |
| Change In Other Current Liabilities | $-1,055,000 | $-754,000 | $-667,000 | $-572,000 |
| Change In Other Current Assets | $-1,179,000 | $0 | - | - |
| Change In Payables And Accrued Expense | $4,435,000 | $6,782,000 | $2,674,000 | $1,664,000 |
| Change In Accrued Expense | $8,021,000 | $3,173,000 | $2,919,000 | $866,000 |
| Change In Payable | $-3,586,000 | $3,609,000 | $-245,000 | $798,000 |
| Change In Account Payable | $-3,586,000 | $3,609,000 | $-245,000 | $798,000 |
| Change In Prepaid Assets | $237,000 | $2,110,000 | $-3,539,000 | $-764,000 |
| Other Non Cash Items | $932,000 | $778,000 | $731,000 | $1,144,000 |
| Stock Based Compensation | $14,288,000 | $11,618,000 | $2,185,000 | $497,000 |
| Amortization Of Securities | $-3,777,000 | $-3,323,000 | $-698,000 | $0 |
| Depreciation Amortization Depletion | $1,006,000 | $536,000 | $364,000 | $37,000 |
| Depreciation And Amortization | $1,006,000 | $536,000 | $364,000 | $37,000 |
| Depreciation | $1,006,000 | $536,000 | $364,000 | $37,000 |
| Net Income From Continuing Operations | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $313,000 |